Original Research

Funksionele beskrywing van ’n faktor VIIa inhiberende peptied, IP-7, geselekteer deur faagblootleggingstegnologie

S.M. Meiring, C.E. Roets, P.N. Badenhorst
Suid-Afrikaanse Tydskrif vir Natuurwetenskap en Tegnologie | Vol 25, No 4 | a162 | DOI: https://doi.org/10.4102/satnt.v25i4.162 | © 2006 S.M. Meiring, C.E. Roets, P.N. Badenhorst | This work is licensed under CC Attribution 4.0
Submitted: 22 September 2006 | Published: 22 September 2006

About the author(s)

S.M. Meiring, Departement Hematologie en Selbiologie, Fakulteit Gesondheidswetenskappe, Universiteit van die Vrystaat, Posbus 339 (G2), Bloemfontein, 9300, South Africa
C.E. Roets, Departement Hematologie en Selbiologie, Fakulteit Gesondheidswetenskappe, Universiteit van die Vrystaat, Posbus 339 (G2), Bloemfontein, 9300, South Africa
P.N. Badenhorst, Departement Hematologie en Selbiologie, Fakulteit Gesondheidswetenskappe, Universiteit van die Vrystaat, Posbus 339 (G2), Bloemfontein, 9300, South Africa

Full Text:

PDF (59KB)

Share this article

Bookmark and Share

Abstract

Die tegniek van faagblootlegging is gebruik om ’n sikliese heptapeptied te selekteer wat met weefselfaktor(WF) kompeteer vir binding aan stollingsfaktor VIIa. Die aminosuurvolgorde van die peptied is Cys-Ala- Trp-Pro-His-Thr-Pro-Asp-Cys (C-AWPHTPD-C) en dit verleng die protrombientyd (PT) op ’n konsentrasie-afhanklike wyse. Die peptied beperk plaatjieklewing aan beide menslike endoteelsel- en weefselfaktormatrikse in ’n vloeikamermodel onder arteriële vloeitoestande. Die peptied funksioneer as ’n volledig mededingende inhibeerder van faktor VIIa met ’n inhibisiekonstante (Ki) van 123,2 μM. In sy huidige vorm is die peptied waarskynlik nie sterk genoeg om verder as antitrombotiese middel ontwikkel te word nie, maar verskillende strategieë kan gevolg word om die werking daarvan te versterk.

Abstract

Functional characterisation of a factor VIIa inhibiting peptide, IP-7 selected by phage display technology
By using the technique of phage display, we selected a cyclic heptapeptide sequence Cys-Ala-Trp-Pro-His-Thr-Pro-Asp-Cys (C-AWPHTPD-C) that competes with tissue factor for binding to coagulation factor VII. This peptide prolongs the prothrombin time (PT) in a concentration dependent way. It also reduces platelet adhesion to both human endothelial cell and tissue factor matrixes in a flow chamber under arterial flow conditions. Furthermore, it acts as a full competitive inhibitor of factor VIIa with an inhibition constant (Ki) of 123,2 μM. In its current form the peptide is probably not sufficiently potent for development as an antithrombotic agent, but different strategies could be followed to reinforce its performance.


Keywords

No related keywords in the metadata.

Metrics

Total abstract views: 1094
Total article views: 1639

Reader Comments

Before posting a comment, read our privacy policy.

Post a comment (login required)

Crossref Citations

No related citations found.